Forty Seven Validates CD47 With 'Don't Eat Me' Tech, Pivotal Studies To Be Initiated In 2020 [Seeking Alpha]
FORTY SEVEN (FTSV)
Last forty seven earnings: 11/12 07:01 am
Check Earnings Report
Company Research
Source: Seeking Alpha
Summary Forty Seven intends to initiate the pivotal phase 3 ENHANCE study exploring magrolimab in combination with azacitidine versus azacitidine alone by Q2 of 2020. Additional results from the phase 1b study using magrolimab in combination with azacitidine to treat higher-risk MDS patients is expected by mid-2020. A phase 3 registration study, using magrolimab plus rituximab to treat patients with relapsed/refractory DLBCL is expected to be initiated by Q1 2020. The biotech anticipates that it will be able to file a BLA for magrolimab to the FDA for the treatment of patients with higher-risk MDS as early as Q4 of 2021. Forty Seven Inc. FTSV CD47 "Don't Eat Me" Target Validated The most important update involves the results released by Forty Seven Inc. for magrolimab in treating patients with AML/MDS. Forty Seven presented positive results from its phase 1b study at the 61st Annual American Society of Hematology conference expected to reach This program is highly synergistic in that
Show less
Read more
Impact Snapshot
Event Time:
FTSV
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
FTSV alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
FTSV alerts
High impacting FORTY SEVEN news events
Weekly update
A roundup of the hottest topics